Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris
The recent FDA approval for a revised version of Rituxan and human hyaluronidase enzyme (rHuPH20) as an easy injection has pointed Halozyme to a string …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
